The Repurpose

The Broad Institute will be searching through Roche's catalog of more than 300 failed compounds to find new possible uses for those drugs, Fierce Biotech reports. "Presumably, those compounds passed initial safety tests, meaning that renewed development for a new use might not require as much lengthy (and expensive) study as a never-before-trialed drug," Fierce Biotech writes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

CRISPR Fight Flares

Over Again

Going Big

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.